Hey that doesn t count up Pagoclone ime was or a waste or the vendor sold a bogus product. They go in 10 mg. pellets, 20 40 [mg] did nada. Are you sure you have Pagoclone [treshold 150 mcg ?]
Yes, I am sure. Be careful and see my
post from an earlier thread. The Netherlands has a serious problem they are doing nothing about with wildly dosed sedative hypnotic research chemicals. Trolls online are rushing and putting inaccurate information on DrugsForum.nl and ruining things. We have our faces covered in soot, do nothing, and don't care because of a few trolls putting inaccurate information online in Dutch only forums. The discrepancies between English forums (American, UK, ect) and Dutch only forums is catastrophic.
You may have had bunk pellets, yet some of the Dutch greymarket pellets are at least 60 light doses per pellet with no safety guidelines or safe way to dose until you dissolve the pellet in solvent and dose out one pellet into 100+ drops. Who is the wild idiot allowing this?
Here are peer reviewed articles for reference.
https://www.biospace.com/indevus-ph...ual-new-clinical-drug-evaluation-unit-meeting
"The Phase II study, known as the EXPRESS trial, was an 8-week, placebo controlled, double-blind, multi-center trial with an open label extension. There were a total of 132 patients randomized in the trial.
Eighty-eight patients received escalating doses of pagoclone from 0.3 mg to 0.6 mg per day. Forty-four patients received placebo. Seventy-nine percent of the patient population was male, which is reflective of the gender distribution of this disorder. Although open label treatment is not blinded, patients and investigators remained blinded to the original treatment allocation during the 8-week double-blind phase."
https://pubmed.ncbi.nlm.nih.gov/11565630/
"Pagoclone is a cyclopyrrolone that is believed to act as a partial agonist at the gamma-aminobutyric acid (GABA)-A/benzodiazepine (BDZ) receptor. In theory, such partial agonists should be anxiolytic but lack the adverse side-effects of sedation, tolerance and withdrawal associated with full GABA-A/BDZ agonists. The objective of the randomized double-blind crossover study was to assess whether pagoclone was an effective anti-panic agent and also to assess its side-effect profile. Patients recruited had a diagnosis of Panic Disorder (DSM-IV) with at least one panic attack per week. Following a 2-week screening period, patients entered a 6-week trial consisting of two 2-week treatment periods, each followed by a 1-week washout.
Patients were randomly assigned to receive either pagoclone 0.1 mg t.d.s. or placebo on their first treatment period and the converse on their second. The primary measure was daily panic attack dairy. Fourteen patients completed the study, the mean number of panic attacks during screening was 5.8+/-0.8 (SEM), this fell to 3.6+/-0.5 during treatment with pagoclone (p = 0.05) and 4.3+/-0.8 with placebo (p = 0.14). There was no significant difference on direct comparison of pagoclone with placebo or in any of the secondary measures (including Rickels withdrawal scale) or the adverse event profiles. The study provides preliminary evidence that pagoclone has anxiolytic properties in the absence of typical BDZ side-effects. This is consistent with its theoretical mode of action as a partial agonist at the GABA(A)/BDZ receptor."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515892/
Pagoclone (CI-1043, IP456) is a novel cyclopyrrolone that pharmacologically is a non selective partial GABAA receptor agonist. A main feature of partial agonists is the limited degree to which they open the ion channel. In comparison, full agonists afford complete opening, allowing uninhibited influx of Ca+ ions while occupying a relative low (~5%) percentage of receptors. Preclinical and clinical studies suggest that pagoclone may have clinical utility as an
anxiolytic agent in the dose range of 0.15 mg BID to 0.6 mg BID, as well as reduced incidence of side-effects when compared to other conventional anxiolytics, specifically diazepam.